Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Upgraded by Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other equities analysts also recently issued reports on TLX. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Trading Down 0.1%

NASDAQ:TLX opened at $7.61 on Friday. Telix Pharmaceuticals has a 1 year low of $7.16 and a 1 year high of $30.36. The stock has a fifty day moving average price of $8.44 and a two-hundred day moving average price of $10.32.

Institutional Trading of Telix Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Pier Capital LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth approximately $3,037,000. Blair William & Co. IL purchased a new position in Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $297,000. Portland Investment Counsel Inc. purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth approximately $1,225,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Telix Pharmaceuticals during the 3rd quarter valued at $243,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.